Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial
Purpose. Survival following biochemical failure is highly variable. Using a randomized trial dataset, we sought to define a risk stratification scheme in men with locally advanced prostate cancer (LAPC). Methods. The TROG 96.01 trial randomized 802 men with LAPC to radiation ± neoadjuvant androgen s...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2012/814724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399286451666944 |
|---|---|
| author | Allison Steigler James W. Denham David S. Lamb Nigel A. Spry David Joseph John Matthews Chris Atkinson Sandra Turner John North David Christie Keen-Hun Tai Chris Wynne |
| author_facet | Allison Steigler James W. Denham David S. Lamb Nigel A. Spry David Joseph John Matthews Chris Atkinson Sandra Turner John North David Christie Keen-Hun Tai Chris Wynne |
| author_sort | Allison Steigler |
| collection | DOAJ |
| description | Purpose. Survival following biochemical failure is highly variable. Using a randomized trial dataset, we sought to define a risk stratification scheme in men with locally advanced prostate cancer (LAPC). Methods. The TROG 96.01 trial randomized 802 men with LAPC to radiation ± neoadjuvant androgen suppression therapy (AST) between 1996 and 2000. Ten-year follow-up data was used to develop three-tier post-biochemical failure risk stratification schemes based on cutpoints of time to biochemical failure (TTBF) and PSA doubling time (PSADT). Schemes were evaluated in univariable, competing risk models for prostate cancer-specific mortality. The performance was assessed by c-indices and internally validated by the simple bootstrap method. Performance rankings were compared in sensitivity analyses using multivariable models and variations in PSADT calculation. Results. 485 men developed biochemical failure. c-indices ranged between 0.630 and 0.730. The most discriminatory scheme had a high risk category defined by PSADT < 4 months or TTBF < 1 year and low risk category by PSADT > 9 months or TTBF > 3 years. Conclusion. TTBF and PSADT can be combined to define risk stratification schemes after biochemical failure in men with LAPC treated with short-term AST and radiotherapy. External validation, particularly in long-term AST and radiotherapy datasets, is necessary. |
| format | Article |
| id | doaj-art-9c071dafa4314d1ebda5d31083faa934 |
| institution | Kabale University |
| issn | 2090-3111 2090-312X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj-art-9c071dafa4314d1ebda5d31083faa9342025-08-20T03:38:22ZengWileyProstate Cancer2090-31112090-312X2012-01-01201210.1155/2012/814724814724Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 TrialAllison Steigler0James W. Denham1David S. Lamb2Nigel A. Spry3David Joseph4John Matthews5Chris Atkinson6Sandra Turner7John North8David Christie9Keen-Hun Tai10Chris Wynne11School of Medicine and Public Health, The University of Newcastle, University Drive, Callaghan, NSW 2308, AustraliaSchool of Medicine and Public Health, The University of Newcastle, University Drive, Callaghan, NSW 2308, AustraliaDepartment of Radiation Oncology, Wellington Cancer Centre, Riddiford Street, Newtown, Wellington 6021, New ZealandDepartment of Radiation Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, WA 6009, AustraliaDepartment of Radiation Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, WA 6009, AustraliaDepartment of Radiation Oncology, Auckland Hospital, 2 Park Road, Grafton, Auckland 1023, New ZealandDepartment of Radiation Oncology, St George’s Cancer Care Centre, 131 Leinster Road, Strowan, Christchurch 8014, New ZealandDepartment of Radiation Oncology, Westmead Hospital, Corner Hawkesbury Road and Darcy Road, Westmead, NSW 2145, AustraliaDepartment of Radiation Oncology, Dunedin Hospital, 201 Great King Street, Dunedin 9054, New ZealandDepartment of Radiation Oncology, Premion, Inland Drive, Tugun, QLD 4224, AustraliaDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, VIC 3002, AustraliaDepartment of Radiation Oncology, St George’s Cancer Care Centre, 131 Leinster Road, Strowan, Christchurch 8014, New ZealandPurpose. Survival following biochemical failure is highly variable. Using a randomized trial dataset, we sought to define a risk stratification scheme in men with locally advanced prostate cancer (LAPC). Methods. The TROG 96.01 trial randomized 802 men with LAPC to radiation ± neoadjuvant androgen suppression therapy (AST) between 1996 and 2000. Ten-year follow-up data was used to develop three-tier post-biochemical failure risk stratification schemes based on cutpoints of time to biochemical failure (TTBF) and PSA doubling time (PSADT). Schemes were evaluated in univariable, competing risk models for prostate cancer-specific mortality. The performance was assessed by c-indices and internally validated by the simple bootstrap method. Performance rankings were compared in sensitivity analyses using multivariable models and variations in PSADT calculation. Results. 485 men developed biochemical failure. c-indices ranged between 0.630 and 0.730. The most discriminatory scheme had a high risk category defined by PSADT < 4 months or TTBF < 1 year and low risk category by PSADT > 9 months or TTBF > 3 years. Conclusion. TTBF and PSADT can be combined to define risk stratification schemes after biochemical failure in men with LAPC treated with short-term AST and radiotherapy. External validation, particularly in long-term AST and radiotherapy datasets, is necessary.http://dx.doi.org/10.1155/2012/814724 |
| spellingShingle | Allison Steigler James W. Denham David S. Lamb Nigel A. Spry David Joseph John Matthews Chris Atkinson Sandra Turner John North David Christie Keen-Hun Tai Chris Wynne Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial Prostate Cancer |
| title | Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial |
| title_full | Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial |
| title_fullStr | Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial |
| title_full_unstemmed | Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial |
| title_short | Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial |
| title_sort | risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer data from the trog 96 01 trial |
| url | http://dx.doi.org/10.1155/2012/814724 |
| work_keys_str_mv | AT allisonsteigler riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial AT jameswdenham riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial AT davidslamb riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial AT nigelaspry riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial AT davidjoseph riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial AT johnmatthews riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial AT chrisatkinson riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial AT sandraturner riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial AT johnnorth riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial AT davidchristie riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial AT keenhuntai riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial AT chriswynne riskstratificationafterbiochemicalfailurefollowingcurativetreatmentoflocallyadvancedprostatecancerdatafromthetrog9601trial |